Press Releases


Latest News


Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
May 22, 2017 | General Releases

Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners
May 11, 2017 | General Releases

Adamas Reports Recent Achievements and First Quarter 2017 Financial Results
May 9, 2017 | Financial Releases

Adamas Reports Inducement Grant to New Chief Operating Officer
May 5, 2017 | General Releases

Adamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017
May 2, 2017 | General Releases

Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102
Apr 27, 2017 | General Releases

Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson's Disease
Apr 24, 2017 | General Releases

Adamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual Meeting
Apr 18, 2017 | General Releases

Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting
Mar 28, 2017 | General Releases

Adamas to Present at the 16th Annual Needham Healthcare Conference
Mar 28, 2017 | General Releases

Pages:  1 2 3 4 5 6 7 8 9 10 11